Results
|
|
66981.
|
|
|
|
66982.
|
|
|
|
66983.
|
|
|
|
66984.
|
|
|
|
66985.
|
|
|
|
66986.
|
|
|
|
66987.
|
|
|
|
66988.
|
|
|
|
66989.
|
|
|
|
66990.
|
|
|
|
66991.
|
|
|
|
66992.
|
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. [electronic resource] by
- Bellmunt, J
- González-Larriba, J L
- Prior, C
- Maroto, P
- Carles, J
- Castellano, D
- Mellado, B
- Gallardo, E
- Perez-Gracia, J L
- Aguilar, G
- Villanueva, X
- Albanell, J
- Calvo, A
Producer: 20120316
In:
Annals of oncology : official journal of the European Society for Medical Oncology vol. 22
Availability: No items available.
|
|
|
66993.
|
|
|
|
66994.
|
|
|
|
66995.
|
|
|
|
66996.
|
|
|
|
66997.
|
|
|
|
66998.
|
|
|
|
66999.
|
|
|
|
67000.
|
|